Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 3, pp. 348-354
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 71
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 731
Open Access | Times Cited: 51
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 46
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 20
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 36
Treatments for COVID-19
Hayden S. Andrews, Jonathan D. Herman, Rajesh T. Gandhi
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 145-157
Closed Access | Times Cited: 28
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access | Times Cited: 1
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 7
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
Gordon Chun‐Kau Chan, Grace Lui, Ngai Sze Wong, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 10, pp. 1406-1412
Open Access | Times Cited: 13
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
The kinetics of SARS-CoV-2 infection based on a human challenge study
Sarafa A. Iyaniwura, Ruy M. Ribeiro, Carolin Zitzmann, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 46
Open Access | Times Cited: 4
Clinical Manifestations of SARS-CoV-2 Infection in Immunocompetent Adults in the Era of Widespread Population Immunity and Omicron Sublineage Viruses
Alexander Shaffer, Eric A. Meyerowitz
Infectious Disease Clinics of North America (2025)
Closed Access
Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir
Kalpana Gupta, William J. O’Brien, Judith Strymish, et al.
Infectious Disease Reports (2025) Vol. 17, Iss. 3, pp. 43-43
Open Access
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 10
Efficacy of antiviral therapy and disease outcomes in COVID-19 patients previously treated with obinutuzumab for follicular lymphoma
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2
Manish C Choudhary, Rinki Deo, Teresa H. Evering, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. 394-402
Closed Access | Times Cited: 3
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
Jaijun Han, Seongman Bae, Ji‐Won Jung, et al.
Medicine (2023) Vol. 102, Iss. 39, pp. e35094-e35094
Open Access | Times Cited: 7
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro
Manoj S. Nair, Maria I. Luck, Yaoxing Huang, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
COVID-19 Therapeutics for Nonhospitalized Patients—Updates and Future Directions
Kara W. Chew, Preeti Malani, Rajesh T. Gandhi
JAMA (2023) Vol. 330, Iss. 16, pp. 1519-1519
Closed Access | Times Cited: 5
<i>In Vitro</i> Antiviral Activity of a New Indol-3-carboxylic Acid Derivative Against SARS-CoV-2
A. N. Narovlyansky, М. В. Филимонова, N. G. Tsyshkova, et al.
Acta Naturae (2024) Vol. 15, Iss. 4, pp. 83-91
Open Access | Times Cited: 1
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Variant-Specific Viral Kinetics in Acute COVID-19
Ruy M. Ribeiro, Manish C. Choudhary, Rinki Deo, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_2, pp. S136-S143
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top